Full Press Release Details
InspireMD Files Amended Registration
For Proposed Public Offering Of Common
MAR 7, 2013 -- InspireMD, Inc. (OTC: NSPR) (the "Company" or "InspireMD") filed an amended registration
statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the resumption of a proposed underwritten
public offering. Under the amended registration statement, the Company is offering $30 million worth of its shares of common stock.
In addition, InspireMD
intends to grant the underwriters a 30-day option to purchase up to an aggregate of 15 percent additional shares of common stock
to cover over-allotments, if any.
The Company intends to
use the proceeds from the offering to support the worldwide commercialization of the MGuardTM Coronary in acute myocardial
infarction, pursue FDA approval in the U.S., to redeem its convertible debentures, and for general corporate purposes.
As part of the offering,
the Company has applied to list its shares of common stock on the NYSE MKT.
A registration statement
relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor
may offers to buy be accepted prior to the time the registration statement becomes effective.
Cowen and Company, LLC
is sole book runner and JMP Securities is acting as co-lead manager. This offering shall be made only by means of a prospectus.
Once available, a prospectus relating to these securities may be obtained from Cowen and Company, LLC (c/o
Broadridge Financial Services) at 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631)
This press release shall
not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
InspireMD is a medical
device company focusing on the development and commercialization of its proprietary stent system technology, MGuard . InspireMD
intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock
is quoted on the OTCBB under the ticker symbol NSPR.
This press release contains
"forward-looking statements." Such statements may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words. Forward-looking statements
are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks
and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual
results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties
include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii)
negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for
the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies,
(v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii)
insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to
successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative
or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers
for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements
in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct
business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications
challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More
detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set
forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Transition Report on
From 10-K/T and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free
of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise
its forward-looking statements as a result of new information, future events or otherwise.
For additional information: